These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16374143)

  • 21. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit.
    Schneider DJ; Aggarwal A
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):903-13. PubMed ID: 15500435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
    Lev EI; Osende JI; Richard MF; Robbins JA; Delfin JA; Rodriguez O; Sharma SK; Jayasundera T; Badimon JJ; Marmur JD
    J Am Coll Cardiol; 2001 Mar; 37(3):847-55. PubMed ID: 11693761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
    Derhaschnig U; Pachinger C; Jilma B
    Am Heart J; 2004 Apr; 147(4):E17. PubMed ID: 15077100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of GPIIb/IIIa inhibition with eptifibatide or tirofiban on the expression of cellular adhesion molecules on monocytes.
    Swoboda S; Walter T; Lang S; Wendel HP; Beyer ME; Griesel E; Hoffmeister HM; Gruettner J
    In Vivo; 2014; 28(5):691-7. PubMed ID: 25189879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
    Neumann FJ; Hochholzer W; Pogatsa-Murray G; Schömig A; Gawaz M
    J Am Coll Cardiol; 2001 Apr; 37(5):1323-8. PubMed ID: 11300442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thromb Haemost; 2005 Jul; 94(1):115-22. PubMed ID: 16113794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR
    Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
    Ahmad S; Jeske WP; Ma Q; Walenga JM; Fareed J
    Thromb Res; 2001 Apr; 102(2):143-51. PubMed ID: 11323025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.
    Untch B; Ahmad S; Messmore HL; Schultz CL; Ma Q; Hoppensteadt DA; Walenga JM; Fareed J
    Thromb Res; 2002 Apr; 106(2):149-56. PubMed ID: 12182915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.
    Dalby M; Montalescot G; Bal dit Sollier C; Vicaut E; Soulat T; Collet JP; Choussat R; Gallois V; Drobinski G; Drouet L; Thomas D
    J Am Coll Cardiol; 2004 Jan; 43(2):162-8. PubMed ID: 14736431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IIb's are not IIb's.
    Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
    Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors.
    Fisher I; Robinson P; Ritter JM
    Br J Clin Pharmacol; 1999 Aug; 48(2):197-9. PubMed ID: 10417496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA; Bozarth JM; Forsythe MS; Slee A
    Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
    Barlage S; Wimmer A; Pfeiffer A; Rothe G; Schmitz G
    Platelets; 2002 May; 13(3):133-40. PubMed ID: 12180495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
    Rukshin V; Shah PK; Cercek B; Finkelstein A; Tsang V; Kaul S
    Circulation; 2002 Apr; 105(16):1970-5. PubMed ID: 11997285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
    Bougie DW; Wilker PR; Wuitschick ED; Curtis BR; Malik M; Levine S; Lind RN; Pereira J; Aster RH
    Blood; 2002 Sep; 100(6):2071-6. PubMed ID: 12200368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.